Covid19: Why aren’t you buying all doses; when will you disburse 50% of doses to states; what is the rationale for differential pricing: SC to CentreThe Leaflet·April 30, 2021
Statement by Indian Civil Society: Need for open innovation and knowledge sharing for COVID-19 healthcare through Indian IP lawsThe Leaflet·June 24, 2020
Plea filed in SC seeking directions to Centre to issue compulsory licenses for patents on Remdesivir, Favipiravir, TocilizumabThe Leaflet·April 29, 2021
COVID-19 and the Shortage of Drugs: A Case for Compulsory LicensingSri Hari Mangalam and Pritish Raj·May 29, 2021
David defeats Goliath: Pune court ruling against US ‘Burger King’ in favour of local competitorVedika Kakar·September 1, 2024
150 years of Gauhar Jaan: Celebrating a star performer light years ahead of her timeSamridhi Shukla·June 26, 2023
Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question?Justice Prabha Sridevan·October 8, 2020
The need for access to anti-TB drugs in India: An interview with Anand GroverSarah Thanawala·April 1, 2023
Is India’s legal framework ready to deal with sexual violence in virtual reality?Gursimran Kaur Bakshi·January 5, 2024
World TB Day coincides with the Indian Patent Office rejecting J&J’s application to extend its patent on anti-tuberculosis drug BedaquilineSarah Thanawala·March 24, 2023